A Rollover Study to Provide Chronic T-1249 to Patients Who Completed Study T1249-102
The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2004 by Trimeris.
Recruitment status was Active, not recruiting
Information provided by:
First received: October 28, 2002
Last updated: June 23, 2005
Last verified: July 2004
Patients who complete study T1249-102 (must be currently failing a T-20 containing regimen to participate in this study) will receive T-1249 at a dose of 200mg daily in combination with a background antiretroviral regimen for 96 weeks. Only patients that participated in study T1249-102 can participate in study T1249-105.
Masking: Open Label
Primary Purpose: Treatment
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Completion T1249-102;
- Currently failing a T-20 containing regimen
- Non-completion of T1249-102.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00048217
|Durham, North Carolina, United States, 27707 |
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||October 28, 2002
||June 23, 2005
||United States: Food and Drug Administration
Keywords provided by Trimeris:
ClinicalTrials.gov processed this record on July 30, 2015